Showing 4 posts of 4 posts found.


Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018
Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …

White blood cells

CHMP recommend white blood cell growth stimulator biosimilar to EMA

July 30, 2018
Sales and Marketing Amgen, CHMP, EMA, Neulasta, biosimilar, chemotherapy, pegfilgrastim

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate …

EMA inside

Sandoz announces biosimilar successes

December 8, 2015
Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim

Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …

FDA sign

FDA accepts regulatory submission for Novartis biosimilar

November 18, 2015
Research and Development, Sales and Marketing Neulasta, Novartis, Sandoz, biosimilar, pegfilgrastim

Novartis’ generics unit Sandoz has announced it has had its Biologics License Application (BLA) for a proposed biosimilar to Amgen’s …

Latest content